
https://www.science.org/content/blog-post/bait-and-switch-type-b-gpcrs
# Bait And Switch For Type B GPCRs (July 2011)

## 1. SUMMARY  
The 2011 commentary highlighted how Class B (secretin‑like) GPCRs—such as the receptors for glucagon, CRF, GHRH, GLP‑1, and PACAP—are naturally activated by relatively large peptide hormones, making the discovery of small‑molecule agonists difficult. At the time, most approved drugs targeting this family were antagonists or peptide‑based therapeutics that required long, synthetically demanding sequences.  

A German research group reported a “click‑chemistry” strategy to accelerate peptide‑agonist discovery for the CRF receptor. They first attached an azide‑bearing C‑terminal peptide (designed to bind the extracellular domain) to a weak agonist fragment bearing an alkyne. The copper‑catalysed azide‑alkyne cycloaddition (CuAAC) produced a conjugate that was >10 000‑fold more potent (nanomolar). By iterating this approach on a 12‑residue scaffold, they identified several variants with picomolar activity, eventually stripping away the extracellular‑domain‑binding “carrier” and retaining a nanomolar agonist composed largely of non‑natural amino acids. The authors argued that this carrier‑conjugate method could speed up ligand screening for other Class B GPCRs and might even be extended to non‑peptidic chemotypes.

## 2. HISTORY  
**Post‑2011 advances in Class B GPCR therapeutics**

| Development | Outcome & Impact |
|-------------|-------------------|
| **Peptide‑based drugs** | The pipeline of peptide agonists for GLP‑1, GIP, and glucagon continued to expand. Semaglutide (2017, later oral formulation 2019) and tirzepatide (2022) achieved blockbuster status, confirming that long‑acting peptide analogues are commercially viable. These molecules were optimized by conventional peptide‑engineering (fatty‑acid acylation, albumin binding) rather than click‑conjugate screening. |
| **CRF‑type 1 receptor (CRF1) antagonists** | Multiple small‑molecule CRF1 antagonists entered Phase II/III (e.g., pexacerfont, verucerfont) but failed to demonstrate efficacy in anxiety or depression trials. No CRF1 agonist has reached the clinic; the field shifted away from CRF modulation toward other stress‑axis targets. |
| **Small‑molecule agonists for Class B GPCRs** | As of 2024, no small‑molecule agonist for a Class B GPCR has received FDA approval. Efforts (e.g., for the glucagon receptor) remain in early discovery, with modest potency and limited oral bioavailability. The structural complexity of the extracellular domain continues to hinder traditional small‑molecule screening. |
| **Click chemistry in peptide drug discovery** | CuAAC has become a routine tool for peptide stapling, labeling, and fragment‑based library construction. However, the specific “carrier‑conjugate” workflow described in the 2011 paper did not become a widely adopted platform for generating clinical candidates. Most commercial peptide programs rely on solid‑phase synthesis and rational design rather than high‑throughput click‑assembly. |
| **Structural biology** | Cryo‑EM structures of several Class B GPCRs (e.g., GLP‑1R, GCGR, CRF1R) were solved between 2015‑2022, revealing the extracellular domain’s role in ligand orientation but also showing that peptide agonists can engage the transmembrane core directly. These data validated the article’s observation that some ligands bypass the extracellular domain, but they also clarified that the extracellular domain still contributes to high‑affinity binding for most native peptides. |
| **Allosteric modulators & biased agonism** | The concept of biased signaling in Class B GPCRs gained traction, leading to the discovery of allosteric modulators (e.g., small‑molecule positive allosteric modulators of the GLP‑1R) that enhance endogenous peptide activity. This line of work diverged from the click‑conjugate approach but addressed the same challenge of achieving drug‑like activation without large peptides. |

Overall, the article’s core insight—that the “middle” of peptide ligands can be treated as a modular scaffold—remains true, but the specific click‑assembly method did not translate into a major pipeline of new drugs. The most consequential progress in the field has come from improving peptide pharmacokinetics (e.g., fatty‑acid conjugation, PEGylation) and from structural breakthroughs that guide rational design.

## 3. PREDICTIONS  
The article implied several future directions. Below are the explicit or implicit predictions and how they fared:

- **Prediction:** *The carrier‑conjugate (click) approach will accelerate screening of new ligands for other Class B GPCRs.*  
  **Reality:** The method is used in academic proof‑of‑concept studies, but it never became a standard high‑throughput platform in industry. Screening for Class B GPCR ligands still relies heavily on peptide synthesis and, increasingly, on structure‑guided design rather than on click‑assembly pipelines.

- **Prediction:** *The approach could be adapted to non‑peptide molecules, eventually yielding small‑molecule agonists.*  
  **Reality:** No small‑molecule agonist for a Class B GPCR has reached the market, and there is no public record of a drug candidate that originated from a click‑linked peptide‑carrier scaffold later converted to a purely small‑molecule scaffold.

- **Prediction (implicit):** *Removing the extracellular‑domain “carrier” will produce potent agonists that act like small‑molecule drugs.*  
  **Reality:** While the authors succeeded in generating nanomolar peptide agonists that bypass the extracellular domain, these molecules remained peptide‑based and required injection. The broader goal of creating orally bioavailable, small‑molecule‑like agonists has not been realized for Class B GPCRs to date.

- **Prediction (implicit):** *Understanding the modular nature of peptide ligands will lead to rapid discovery of new therapeutics.*  
  **Reality:** The modular concept informed later peptide‑engineering strategies (e.g., stapled peptides, macrocycles), but the timeline for bringing new drugs to patients remained on the order of a decade, not the rapid acceleration suggested.

## 4. INTEREST  
**Rating: 6/10** – The article is a solid snapshot of a creative chemistry‑driven attempt to tackle a known drug‑discovery bottleneck. It is historically interesting for illustrating early use of click chemistry in GPCR research, but its direct influence on later therapeutics appears modest.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110727-bait-and-switch-type-b-gpcrs.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_